United States · Seed startup

Who invested in Meliora Therapeutics

One round we have observed, with the 4 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$11Mraised across 1 round since 2022, from 1 source

Latest round
Seed, $11MSept 2022
Investors
4
See who backed them

The rounds

  1. Sept 2022

Everyone who backed them

ZhenFundVC firm1round
Village GlobalVC firm1round
Obvious VenturesAccelerator1round
HOF CapitalVC firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 2 firms list Meliora Therapeutics as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.

HawktailVC firmPer its own site
Valkyrie FundAcceleratorPer its own site

Quick answers about Meliora Therapeutics

Who invested in Meliora Therapeutics?

Meliora Therapeutics's investors include ZhenFund, Village Global, Obvious Ventures and HOF Capital.

How much has Meliora Therapeutics raised?

Meliora Therapeutics has raised $11M across 1 round since 2022.

When did Meliora Therapeutics last raise?

Meliora Therapeutics's most recent round was a Seed of $11M in Sept 2022.

What was Meliora Therapeutics's biggest round?

Its most recent round, $11M in Sept 2022, is also its largest on record.

Who backed Meliora Therapeutics first?

Meliora Therapeutics's first round on record, in Sept 2022, was backed by ZhenFund, Village Global and Obvious Ventures and 1 others.

What stage is Meliora Therapeutics at?

Meliora Therapeutics's latest named round is a Seed, in Sept 2022.

Where is Meliora Therapeutics based?

Meliora Therapeutics is based in the United States.

Companies like Meliora Therapeutics

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.